AGL 37.95 Decreased By ▼ -0.07 (-0.18%)
AIRLINK 211.75 Increased By ▲ 14.39 (7.29%)
BOP 9.68 Increased By ▲ 0.14 (1.47%)
CNERGY 6.40 Increased By ▲ 0.49 (8.29%)
DCL 9.23 Increased By ▲ 0.41 (4.65%)
DFML 37.52 Increased By ▲ 1.78 (4.98%)
DGKC 99.18 Increased By ▲ 2.32 (2.4%)
FCCL 35.90 Increased By ▲ 0.65 (1.84%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 14.27 Increased By ▲ 1.10 (8.35%)
HUBC 131.25 Increased By ▲ 3.70 (2.9%)
HUMNL 13.75 Increased By ▲ 0.25 (1.85%)
KEL 5.53 Increased By ▲ 0.21 (3.95%)
KOSM 7.27 Increased By ▲ 0.27 (3.86%)
MLCF 45.25 Increased By ▲ 0.55 (1.23%)
NBP 61.61 Increased By ▲ 0.19 (0.31%)
OGDC 222.50 Increased By ▲ 7.83 (3.65%)
PAEL 41.22 Increased By ▲ 2.43 (6.26%)
PIBTL 8.49 Increased By ▲ 0.24 (2.91%)
PPL 201.25 Increased By ▲ 8.17 (4.23%)
PRL 39.85 Increased By ▲ 1.19 (3.08%)
PTC 27.60 Increased By ▲ 1.80 (6.98%)
SEARL 108.88 Increased By ▲ 5.28 (5.1%)
TELE 8.59 Increased By ▲ 0.29 (3.49%)
TOMCL 36.00 Increased By ▲ 1.00 (2.86%)
TPLP 13.80 Increased By ▲ 0.50 (3.76%)
TREET 24.38 Increased By ▲ 2.22 (10.02%)
TRG 61.15 Increased By ▲ 5.56 (10%)
UNITY 34.30 Increased By ▲ 1.33 (4.03%)
WTL 1.69 Increased By ▲ 0.09 (5.63%)
BR100 12,123 Increased By 396.3 (3.38%)
BR30 37,654 Increased By 1277.8 (3.51%)
KSE100 113,250 Increased By 3737 (3.41%)
KSE30 35,784 Increased By 1270.4 (3.68%)
World

Aspirin does not improve survival in COVID-19 patients: UK study

  • The scientists behind the trial, which is looking into a range of potential treatments for COVID-19, evaluated aspirin's effects on nearly 15,000 hospitalised patients infected with the novel coronavirus.
  • In the study, named RECOVERY, a little less than half of the patients were selected at random and given 150mg of aspirin once a day, and the remaining were given usual care alone.
Published June 8, 2021

Aspirin does not improve the chances of survival in severely ill COVID-19 patients, early results from one of Britain's biggest trials studying the commonly used painkiller and blood thinner showed on Tuesday.

The scientists behind the trial, which is looking into a range of potential treatments for COVID-19, evaluated aspirin's effects on nearly 15,000 hospitalised patients infected with the novel coronavirus.

Since the drug helps reduce blood clots in other diseases, it was tested in COVID-19 patients who are at a higher risk of clotting issues.

"Although aspirin was associated with a small increase in the likelihood of being discharged alive, this does not seem to be sufficient to justify its widespread use for patients hospitalised with COVID-19," said Peter Horby, co-chief investigator of the trial.

In the study, named RECOVERY, a little less than half of the patients were selected at random and given 150mg of aspirin once a day, and the remaining were given usual care alone.

The trial, run by the University of Oxford, is also looking at the effectiveness of several other treatments, and was the first to show that the widely available steroid dexamethasone, could save lives of people severely ill with COVID-19.

The aspirin study did not show any significant change to the risk of patients progressing to invasive mechanical ventilation. For every 1,000 patients treated with the medicine, about six more patients experienced a major bleeding event and about six fewer experienced a clotting event, Oxford said.

Oxford said the results would be published on online portal medRxiv, and have been submitted for publication at a peer-reviewed medical journal.

RECOVERY also showed anti-inflammatory treatment tocilizumab significantly reduced deaths, but found no benefit for COVID-19 patients from drugs such as antibiotic azithromycin and anti-malarial drug hydroxychloroquine.

Comments

Comments are closed.